| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 575 | 72 | 3.257 | 27.800 | 3.027 | 1.216 | 1.926 | 3.453 | 4.116 | 1.405 |
| Total Income - EUR | 575 | 72 | 3.257 | 27.887 | 3.777 | 1.258 | 1.929 | 3.453 | 4.116 | 1.405 |
| Total Expenses - EUR | 200 | 37 | 338 | 1.215 | 496 | 462 | 298 | 670 | 2.710 | 1.099 |
| Gross Profit/Loss - EUR | 375 | 36 | 2.919 | 26.672 | 3.281 | 796 | 1.631 | 2.783 | 1.406 | 307 |
| Net Profit/Loss - EUR | 367 | 34 | 2.821 | 25.835 | 3.168 | 758 | 1.573 | 2.679 | 1.181 | 258 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Nefroline Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 1.836 | 1.817 | 1.498 | 1.004 | 526 | 145 | 0 | 0 | 731 | 0 |
| Current Assets | 1.227 | 1.251 | 6.694 | 30.449 | 33.453 | 1.358 | 3.171 | 4.220 | 4.320 | 1.646 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 444 | 0 | 0 | 0 | 1.091 | 2.636 | 0 | 271 |
| Cash | 1.227 | 1.251 | 6.249 | 30.449 | 33.453 | 1.358 | 2.080 | 1.584 | 4.320 | 1.376 |
| Shareholders Funds | 1.694 | 1.347 | 4.503 | 30.256 | 3.218 | 808 | 2.363 | 2.728 | 1.273 | 1.523 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 1.369 | 1.722 | 3.689 | 1.197 | 30.761 | 695 | 808 | 1.492 | 3.778 | 123 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Nefroline Med Srl